Chinese companies new crown vaccine research and development rigorous
Former Shanghai CDC vaccine expert Tao Li Na said in an interview with the "Securities Daily" reporter, although China's independent research and development of the new crown vaccine did not publish clinical trial data, but also published some emergency use of the situation, such as the chairman of the Sinopharm Group, said that it has been used on nearly a million people, did not receive a case of Serious adverse reactions have been reported, only individual some minor symptoms.
Tao Liner said: "Because the vaccine clinic is a very rigorous scientific experiment, China's new crown vaccine may be announced through papers and other forms, so it will take more time. The effectiveness information of the foreign new crown vaccine is the R & D companies announced to the media, not in the form of papers, so from the scientific point of view is not rigorous enough. China's new crown vaccine R & D progress announced late, also shows that we are more cautious attitude, especially China's new crown vaccine phase III clinical trials are abroad, more uncontrollable factors."
Not long ago, the authoritative medical journal The Lancet published a peer-reviewed paper on the Chinese vaccine, concluding that the new crown vaccine developed by China's Kexing Biologicals could rapidly induce an immune response over a four-week period, making it suitable for use during a pandemic. According to the article, the results of large-scale late-stage trials, or Phase III clinical trials, are particularly important to determine whether the immune response triggered by China's Xinguan vaccine protects people from infection, and the duration of the antibody response must be studied in the future.
China currently has four new crown vaccines in Phase III clinical trials in more than a dozen countries around the world, including two inactivated vaccines from Sinopharm, an inactivated vaccine from Kexing, and an adenovirus-vectored vaccine developed by Kang Xinuo in collaboration with academician Chen Wei. Some of these vaccines have completed mass production, and countries such as Turkey have begun to negotiate bookings. Domestic such as Sichuan Province has begun the procurement of domestic new crown vaccine, the introduction of the Kexing new crown vaccine price of 200 yuan / piece.
Tao Li Na believes that China's own research and development of the new crown vaccine subjects did not receive reports of serious adverse reactions, to a certain extent, to prove the effectiveness of the domestic new crown vaccine, the next step is to wait for the moment of surprise.
Promoting the upgrading of China's vaccine research and development
According to data released by market research organization EvaluatePharma, the global vaccine market size of about $32.5 billion in 2019, ranking fourth among all therapeutic areas, with a market share of about 3.6%. The global vaccine market has formed an oligopolistic competitive pattern, and the vaccine businesses of the four major vaccine giants GlaxoSmithKline (GSK), Merck Sharp & Dohme, Pfizer, and Sanofi realized revenues of $8.481 billion, $7.967 billion, $6.716 billion, and $6.504 billion, respectively, and collectively accounted for more than 90% of the global vaccine market share in 2019.
Unlike the high concentration of the global vaccine market, China's vaccine industry has entered the market for more than two decades, so the vaccine market pattern is relatively fragmented. According to incomplete statistics, there are more than 300 domestic vaccine approvals in China, and more than 50 vaccine companies. China Biotechnology Corporation, a subsidiary of Sinopharm Group, is the leading vaccine company in China, with biologics research institutes in Beijing, Shanghai, Wuhan, Chengdu, Changchun, Lanzhou, etc., which have more than half of the vaccine approvals.
In recent years, China's self-developed vaccine products have been listed one after another, and R & D investment has risen year by year. 2020, Xiamen Wantai Canghai bivalent HPV vaccine, Watson Biological 13-valent Pneumococcal Polysaccharide Conjugate Vaccine, Changchun Baxter Nasal Spray Influenza Vaccine has been approved for listing to launch the monopoly of the international vaccine companies. "Securities Daily" reporter statistics, the Oriental wealth biological vaccine plate of 55 listed companies, 46 companies in 2019, the year-on-year increase in research and development costs, 38 companies in 2020 semi-annual report of research and development costs rose year-on-year.
Wang Ruiyan, a medical researcher at the Huaxia Happiness Research Institute, told the Securities Daily reporter that although the clinical trials of vaccines by Chinese biopharmaceutical companies have increased significantly in recent years, but just as the relationship between originator drugs and generics, the research and development of many domestic vaccines is to imitate Western product practices, and only a few vaccines, such as HPV (human papillomavirus), have independent intellectual property rights.
Vaccine industry development constraints, on the one hand, the vaccine product development cycle is long, the input cost is large, innovative vaccines from the concept to market the entire process generally takes 8 to 12 years; on the other hand, there is a certain degree of difficulty in the large-scale industrialization, the vaccine industry, quality control requirements are high, the requirement to control the entire production process, which is in the development of China's biomedical enterprises, with the technology and the scale of the difficulty.
The research and development of the new crown vaccine breaks this barrier, the provinces and cities this year to actively start the vaccine R & D base project. In May this year, Ruike Bio and Jiangsu Center for Disease Control and Prevention, Taizhou Pharmaceutical Park tripartite cooperation, the first in the province to start the recombinant new crown vaccine R & D project. July Amei Rongan virus vaccine industrialization base in the Ningbo Free Trade Zone laid the foundation stone, which is the first new crown vaccine production base project in Zhejiang Province.
According to WHO statistics, as of October 15, there are more than 190 kinds of candidate new crown vaccine is being developed globally, of which there are 22 in China, ranking second only to the United States of 36, China's multiple vaccine research and development has been in the international first square.
The new crown vaccine supply gap of more than two years
Not only China's vaccine industry on the world stage, the capital market has also given biomedical enterprises higher valuation and capital support. Shenzhen Zhongjin Huachuang Fund Chairman Gong Tao said in an interview with the "Securities Daily" reporter, the biological vaccine plate is now the capital market is popular, and with the new crown vaccine research and development is increasingly clear, investors are also from the expected future market prospects to look at the advantages of the talent, to look at the level of experience of the R & D team, to look at the strength of the shareholders to change.
Gong Tao said: "For example, the R & D team from Sanofi Pasteur, AstraZeneca, Pfizer and other world-class giants, and this company currently has 16 innovative vaccine products in 13 disease areas in the R & D, the main technical cooperation is the Chinese Academy of Military Sciences, so both from the perspective of R & D team or industry experience is the industry's top. Its new crown vaccine development has entered phase III clinical, this new crown vaccine development or become a litmus test of the company's success or not."
Gong Tao believes that from the new crown vaccine R & D process, China's vaccine R & D capacity has reached the world's leading level, but from the enterprise scale, the global competitiveness of China's vaccine enterprises is still weak. The face of the global four vaccine oligopoly siege, China's vaccine enterprises to kill out a technology and quality to win the reputation; the second need for policy and capital support. This time China's new crown vaccine research and development speed is not weaker than foreign countries, is a multi-factor **** the same force.
As the new crown vaccine research and development into the end, its market demand is also increasingly clear. Recently, Zhang Wenhong, director of the Department of Infectious Diseases at Huashan Hospital of Fudan University, said that if strong interventions are not taken, the new crown outbreak will continue to spread as a "resident virus", and it will be difficult to stop the spread of the virus if less than 60% of the population is vaccinated with the new crown vaccine.
Luo Guoqing, head of the index investment department of the Guangfa Fund, said that all the vaccines may be listed in the year, the total dose of the vaccine is not more than 1 billion doses, far from meeting the market demand, so at least in the next two to three years, the new crown vaccine market is still a large supply gap, which is the corresponding domestic vaccine research enterprises and suppliers of the performance of the vaccine will play a better role in supporting.
Jiang Han, a senior researcher at Pangu Wisdom Center, told the Securities Daily reporter: "The investment value of the vaccine concept stocks, in the short term, comes from the potential demand for the new crown vaccine market in the future. In the long term, the new crown vaccine allows China's biopharmaceutical companies to go global, with core competitiveness of the company will be under the brand and market influence, to obtain a broader space for growth."